ERICA可预测老年乳腺癌女性对他莫昔芬的反应。
ERICA predicts response to tamoxifen in elderly women with breast cancer.
作者信息
Davies N, Moir G, Carpenter R, Cuthbert A, Herbert A, Royle G T, Taylor I
机构信息
University Surgical Unit, Southampton General Hospital.
出版信息
Ann R Coll Surg Engl. 1991 Nov;73(6):361-3.
Abstract
Oestrogen receptor status has been determined by an immunocytochemical assay using fine-needle aspiration samples of primary breast cancers in elderly patients. In a prospective study 56 patients were treated with tamoxifen only. Satisfactory assays were achieved in 49 patients. Disease was controlled by tamoxifen in 32 of 35 (91%) patients with oestrogen receptor positive tumours, compared with only 1 (7%) of 14 who were receptor negative. Immunocytochemical assay on fine-needle aspiration samples is relatively non-invasive and simple to perform, it accurately predicts response to tamoxifen in elderly patients and can be used to select patients for tamoxifen only therapy.
摘要
雌激素受体状态通过免疫细胞化学分析法测定，该方法使用老年患者原发性乳腺癌的细针穿刺样本。在一项前瞻性研究中，56例患者仅接受他莫昔芬治疗。49例患者获得了满意的检测结果。在35例雌激素受体阳性肿瘤患者中，32例（91%）的疾病通过他莫昔芬得到控制，相比之下，14例受体阴性患者中只有1例（7%）得到控制。对细针穿刺样本进行免疫细胞化学分析相对无创且操作简单，它能准确预测老年患者对他莫昔芬的反应，可用于选择仅接受他莫昔芬治疗的患者。
相似文献
1
ERICA predicts response to tamoxifen in elderly women with breast cancer.ERICA可预测老年乳腺癌女性对他莫昔芬的反应。
Ann R Coll Surg Engl. 1991 Nov;73(6):361-3.
2
3
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.通过乳腺癌患者生物标志物的表达预测他莫昔芬初始治疗的临床结局
Clin Cancer Res. 2000 Feb;6(2):616-21.
4
[The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].[类固醇受体对乳腺癌患者预后及激素治疗的重要性：荷兰东南部的一项回顾性研究]
Ned Tijdschr Geneeskd. 1998 Aug 1;142(31):1772-8.
5
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.前列腺特异性抗原（PSA）的表达与复发性乳腺癌对他莫昔芬治疗的不良反应相关。
Br J Cancer. 1999 Feb;79(5-6):888-94. doi: 10.1038/sj.bjc.6690142.
6
Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.老年雌激素受体阳性原发性乳腺癌的生物学特征及对原发性内分泌治疗的反应
Crit Rev Oncol Hematol. 2009 Oct;72(1):76-82. doi: 10.1016/j.critrevonc.2009.01.005. Epub 2009 Jun 9.
7
Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women.老年女性淋巴结阳性乳腺癌患者接受他莫昔芬治疗后的生物标志物与预后
Br J Cancer. 2000 Jan;82(2):270-7. doi: 10.1054/bjoc.1999.0914.
8
Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.利用雌激素受体信息在美国推广乳腺癌辅助多药化疗和他莫昔芬：1975 - 1999年
J Natl Cancer Inst Monogr. 2006(36):7-15. doi: 10.1093/jncimonographs/lgj003.
9
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.原发性乳腺癌新辅助化疗内分泌治疗反应的预测
Clin Cancer Res. 1997 Apr;3(4):593-600.
10
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.激素受体阳性的绝经前原发性乳腺癌中的HER2状态可提供预后信息，但不能预测他莫昔芬的治疗效果。
Breast Cancer Res Treat. 2008 May;109(2):351-7. doi: 10.1007/s10549-007-9660-2. Epub 2007 Jul 18.
引用本文的文献
1
pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.pS2蛋白：一种可改善绝经后乳腺癌患者对新辅助他莫昔芬反应预测的标志物。
Br J Cancer. 1996 Oct;74(7):1120-5. doi: 10.1038/bjc.1996.500.
2
Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription-polymerase chain reaction.
Br J Cancer. 1995 Dec;72(6):1427-34. doi: 10.1038/bjc.1995.525.
3
Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry.使用单针细针穿刺活检结合免疫细胞化学染色和流式细胞术来确定预测乳腺癌对原发性药物治疗反应的因素。
Virchows Arch. 1995;426(2):155-61. doi: 10.1007/BF00192637.
4
Treating elderly patients with breast cancer.治疗老年乳腺癌患者。
BMJ. 1992 May 23;304(6838):1377. doi: 10.1136/bmj.304.6838.1377.
5
The differing predictive values of oestrogen receptor assays for large breast cancers.雌激素受体检测对大型乳腺癌的不同预测价值。
Postgrad Med J. 1992 Nov;68(805):900-3. doi: 10.1136/pgmj.68.805.900.
本文引用的文献
1
Monoclonal antibodies to human estrogen receptor.抗人雌激素受体单克隆抗体。
Proc Natl Acad Sci U S A. 1980 Sep;77(9):5115-9. doi: 10.1073/pnas.77.9.5115.
2
Oestrogen receptors and breast cancer: current status.雌激素受体与乳腺癌：现状
Br J Surg. 1980 Mar;67(3):153-69. doi: 10.1002/bjs.1800670302.
3
Primary treatment of breast cancer in elderly women with Tamoxifen.他莫昔芬用于老年女性乳腺癌的初始治疗。
Clin Oncol. 1983 Mar;9(1):31-4.
4
Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study.他莫昔芬作为老年女性局部乳腺癌的初始单一治疗：一项试点研究。
Br Med J (Clin Res Ed). 1982 Mar 20;284(6319):869-70. doi: 10.1136/bmj.284.6319.869-a.
5
Assessment of a scoring scheme for the preoperative diagnosis of breast lumps.
Ann R Coll Surg Engl. 1984 Jul;66(4):267-9.
6
Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells.单克隆抗体将雌激素受体定位在靶细胞核中。
Nature. 1984;307(5953):745-7. doi: 10.1038/307745a0.
7
Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy.
Lancet. 1981 Dec 12;2(8259):1317-9. doi: 10.1016/s0140-6736(81)91341-6.
8
Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management.他莫昔芬作为老年或体弱乳腺癌患者的一线治疗：实用管理方法
Br Med J (Clin Res Ed). 1985 Feb 2;290(6465):358. doi: 10.1136/bmj.290.6465.358.
9
Fine needle aspiration cytology of breast masses: an evaluation of its accuracy and reasons for diagnostic failure.乳腺肿块的细针穿刺细胞学检查：其准确性及诊断失败原因的评估
Ann R Coll Surg Engl. 1987 Jul;69(4):156-9.
10
The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer; correlation with biochemical assay and prediction of response to endocrine therapy.乳腺癌细针穿刺抽吸物中雌激素受体的细胞化学检测；与生化检测的相关性及对内分泌治疗反应的预测
Br J Cancer. 1988 Jul;58(1):77-80. doi: 10.1038/bjc.1988.166.
Zotero 插件